Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS ’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.
News|Articles|August 1, 2025
How One Brand Protected Market Share Amid Biosimilar Pressure
Author(s)SamaCare
Case study on how one mature/late stage biopharmaceutical brand leveraged SamaCare’s insights and intervention platform to decrease administrative related discontinuations of their drug and maintain market share during a biosimilar release.
Advertisement
Advertisement
Related to this article
Cencora’s Matt Sample and Gregg Gorniak explain why AI should recommend, not decide, and why pharma needs an agent strategy before chasing use cases.
With a lawsuit, a House delay bill and drugmaker intervention motions in play, here's where HRSA's 340B rebate pilot stands ahead of Jan. 1.
In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
CSafe's Aaron Mantia explains how lane, temperature range, duration and product cost shape thermal protection choices for bulk air cargo.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how automation cuts human touches, enforces quarantine and consolidates cold storage.
PAXAFE's Mark Talens explains why real-time visibility starts with process redesign and how it speeds cold chain disposition decisions.
FDA’s final guidance on prescription drug use-related software clarifies when companion app content is labeling, promotion or belongs in the PI.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Inside the 340B Rebate Pilot Standoff: Court, Congress, Drugmakers
2
Pharma Pulse: Cencora to Acquire AON, Amazon and Google Back ePA Expansion
3
Is Pharma Moving Too Fast on AI Agents?
4
FDA Finalizes Guidance on Prescription Drug Companion Apps
5